January 26, 2021

The Niche

Trusted stem cell blog & resources

IPS cells cancer

2 min read

A few times a month I do a recommended reads kind of post on more than just stem cells, which people seem to appreciate as a condensed list of new science and medicine. Scientists might ask each other, “what’s in your to-read list?” rather than “what’s in your wallet?” Here are some of the things I’m hoping to get to in coming days or have already taken a look at that seem worth a read. If you want to see last week’s reads here …Read More

2 min read

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work led by Dr. Masayo Takahashi. The new heart disease study is led by Yoshiki Sawa. This appears to be the third conditionally approved IPS cell study in Japan. I’m not …Read More

2 min read

Just how tumorigenic are iPS cells?  The field really doesn’t know at this point. However, a steady stream of papers have raised red flag after red flag about genomic and epigenomic alterations/mutations that are linked to cancer. Of course, then there is the fact that all the genetic changes actually used to make reprogrammed cells in the first palce are linked to cancer: not just Myc, but also Nanog, KLF4, Sox2, loss of p53 function, etc. We all first thought that making iPSCs without …Read More